4559 — Zeria Pharmaceutical Co Cashflow Statement
0.000.00%
- ¥89bn
- ¥107bn
- ¥87bn
- 96
- 79
- 68
- 95
Annual cashflow statement for Zeria Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 3,923 | 5,722 | 7,273 | 9,508 | 12,619 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -65.7 | 439 | 169 | -1,702 | -47.9 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1,399 | -2,481 | -433 | -3,178 | -7,203 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 6,894 | 9,080 | 13,157 | 12,184 | 12,922 |
Capital Expenditures | -16,133 | -1,421 | -2,658 | -3,899 | -2,734 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -1,328 | -1,472 | 83.2 | -53.6 | 1,683 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -17,461 | -2,893 | -2,575 | -3,952 | -1,051 |
Financing Cash Flow Items | -3.23 | -3.52 | -3.93 | -1.49 | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 11,185 | -4,841 | -7,415 | -8,124 | -7,757 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 789 | 1,910 | 4,515 | 2,510 | 4,864 |